We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
The ASX200 didn’t seem to be able to recover from the CPI inflation data (April) read – showing a ri...
Read ArticleBiotech tends to follow a four to five year market cycle and those in the sector say there are signa...
Read ArticleWhat stocks trading at 52-week highs are telling us How do we know if they are overbought or overso...
Read ArticleASX 200 closes significantly lower Mining Sector sheds -3.2% after BHP goes ex-div Small caps led...
Read ArticleASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market a...
Read ArticleThe S&P ASX 200 was down 2.5% in May, with mid caps performing the best and small caps lagging...
Read ArticleASX benchmark ends the day flat, but not for lack of trying to rise. Or fall Tech stocks fell hard...
Read ArticleRBA Board kicks the nation in the goolies again, demanding another 25 basis points Investors seemin...
Read ArticleThe S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chi...
Read ArticleThe benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win th...
Read ArticleThe S&P ASX 200 follows US markets closing fairly flat up 0.07%, while the S&P XEC is up 0....
Read ArticleASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of pos...
Read ArticleBenchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleASX down, then up, then down even further to -1.4% as bank crisis looms large. XEC Emerging Compani...
Read ArticleASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge nega...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleRooLife is today’s ASX winner after getting its drinks into China’s massive Freshippo market The Be...
Read ArticleThe ASX recovered from an early stumble to finish the day up-ish Meta wants you to pay $12 a month...
Read ArticleThe ASX 200 fell 0.21% and the ASX XEC slips 1.05% A 8 out of 11 sectors were lower led by Consumer...
Read ArticleExopharm (EX1) shares tumble following the company’s bid to raise $2.1 million The company signed...
Read ArticleASX slumps even lower after lunch to end the day down around 0.5% China’s demands for the return of...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleWith various studies identifying exosomes as a preferred drug-delivery option for some mRNA therapeu...
Read ArticleExopharm will move to another important stage in a collaboration agreement with a major global pharm...
Read ArticleMoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We...
Read ArticleExopharm’s technology has put the company in a leadership-position in both naïve exosomes and engine...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleDr Boreham’s Crucible By Tim Boreham ASX code: ((IIQ)) Share price: 67 cents Market cap: $59.8 milli...
Read ArticleWith a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals...
Read ArticleQuarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin...
Read ArticleFirst up, ladies and gents, inflation has spiked way above what the RBA and everyone else was expect...
Read ArticleThe ASX microcaps Emerging Companies index closed 0.01% higher on Friday Copper explorer Stelar Met...
Read ArticleThe ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down...
Read ArticleFounded less than a decade ago with a mission to harness the unique properties of exosomes as a new...
Read ArticleExopharm (ASX:EX1) has signed a Master Collaborative Services Agreement with the Astellas In...
Read ArticleAstellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top...
Read ArticleThe granting of a US patent for Exopharm’s LEAP technology places the company in the top tier of glo...
Read ArticleUS Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP exosome purifi...
Read ArticleExopharm Limited (EX1) announced the company has been granted a US patent for its proprietary LEAP...
Read ArticleWall Street rallies as sentiment lifts US and European stock markets finally rose overnight after th...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleMoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and...
Read ArticleThe key appointments announced today will help Exopharm to engage international players, and support...
Read ArticleThe ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrand...
Read ArticleShareCafeA new cell technology for transformative medicine delivery Chris Baldwin – Deputy CEO &...
Read ArticleShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with pres...
Read ArticleThe patent for Exopharm’s LEAP technology has been granted by the Russian Patent Office. Exosome med...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleMelbourne biotech company Exopharm (ASX:EX1) has received firm commitments from institutional and so...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleSummary Exopharm obtained firm commitments from institutional and sophisticated investors to rai...
Read ArticleExopharm (ASX:EX1) says it has received 'firm commitments' from institutional and sophistica...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSource: smolaw, Shutterstock Summary A leader in human clinical therapeutics, Exopharm Limited...
Read ArticleSource: katjen, Shutterstock The market could not extend yesterday's gains to today's session and t...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticlePitt Street Research has initiated coverage on Melbourne biotech company Exopharm (ASX:EX1), declari...
Read ArticleSource: Ratanapon Srisuneton, Shutterstock Summary Universal Biosensors has entered into exclus...
Read ArticleSource: Oleksiy Mark, Shutterstock Summary Exopharm reported positive safety outcomes and valid...
Read ArticleThe Exopharm Ltd (ASX: EX1) share price rocketed today after the company announced positive clinica...
Read ArticleShares in Exopharm (ASX:EX1) jumped this morning after the Melbourne biotech announced it was buildi...
Read ArticleExopharm (ASX:EX1), which is developing medicines using exosomes from cells, has announced d...
Read ArticleWall Street finishes on record highs again after strong US jobs data Dow Jones and S&P500 closed...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike....
Read ArticleThe Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinica...
Read ArticleSpecial Report: Exopharm (ASX:EX1) is picking up steam as the scientific community wakes up to the h...
Read ArticleSpecial Report: Melbourne biotech Exopharm (ASX:EX1) has solved a crucial bottleneck in the producti...
Read ArticleSpecial Report: Biotech company Exopharm has begun its second human clinical trial using extracellul...
Read ArticleShareCafeHidden Gems Webinar Recap – NMT, EX1, DCC, OVN Catch up on the full webinar with presentati...
Read ArticleShareCafeExopharm – Hidden Gems Webinar Presentation Presenter – Chris Baldwin – Chief Operating...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, August 27. Data is taken after the mar...
Read ArticleCanary Capital is making a huge bet on a company that thinks stem cells aren’t the future of medicin...
Read ArticleShareCafeExopharm’s Big Idea Heading For A Big Business In EV Medicines Everyone is familiar with ho...
Read ArticleClinical stage regenerative medicine company Exopharm (ASX: EX1) has published test results that sug...
Read ArticleSmartphone screen protector maker Nanoveu (ASX:NVU) is running hard this morning after receiving mor...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleThe COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand th...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleRegenerative medicine company Exopharm (ASX: EX1) has received amiable results from a BioMAP testing...
Read ArticleMany regenerative medicine companies on the ASX specialise in stem-cell therapies but Exopharm (ASX:...
Read ArticleMelbourne-based regenerative medicine company Exopharm (ASX:EX1) has announced the first dos...
Read ArticleCann Group (ASX:CAN) is pulling back from its original ambitious Mildura cannabis growing warehouse,...
Read ArticleExopharm (EX1) has announced the first dosing has occurred in the PLEXOVAL Phase 1 study using exos...
Read ArticleThe science of Regenerative Medicine is a rapidly emerging field linking the medical technology, bio...
Read ArticleRegenerative medicine company Exopharm (ASX:EX1) has announced the start of its PLEXOVAL Pha...
Read ArticleWant to know when shares are coming out of escrow? We’ve been keeping tabs, so you don’t have to. Ev...
Read ArticleSpecial Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the emb...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
